Vaccines for Human Papilloviruses Infection and Anogenital Disease
|
Edited By:Robert W. TindleRoyal Children's Hospital - Herston ISBN: 978-1-57059-589-9 Published: 1999-10-01 This book may be purchased as an eBook (pdf) for $99, or individual chapters (pdf) may be purchased from the list below for $19. |
Human papillomavirus-associated genital warts are now the most commonly seen sexually transmitted disease. Human papillomavirus-associated cervical cancer is a major cause of death on women around the world. Efforts are being taken to prevent or treat these diseases with vaccines. This book specializes on vaccines for papillomavirus- related disease. It brings together for the first time the advances of the major research groups in the field, and highlights the current progress being made from the laboratory bench to clinical trials.
Chapters available from this book
Live Recombinant Vaccine Vectors for HPV Antigens Associated with Infection and Malignancy
Abba C. Zubair, Yvonne Paterson and Elwyn Y. Loh
Classical vaccines for polio, small pox, and influenza use attenuated viruses to induce immunity in diseases where first time exposure normally elicits protective immunity against a second infection with the same or closely related agent. These vaccines are successful because the diseases in huma...
Experimental Vaccine Strategies for Cancer Immunotherapy
Stefanie L. Stevenson and T.C. Wu
The ideal cancer therapy for advanced cervical cancers should have the potency to eradicate systemic tumor in multiple sites in the body, as well as the specificity to discriminate between neoplastic and nonneoplastic cells. In both of these respects, immunotherapy is an attractive approach. The i...
DNA Vaccines for Papillomavirus Infections
Sancy A. Leachman and Janet L. Brandsma
The major advances in approaches in vaccinology can be subdivided into three “waves”, each resulting from breakthrough technologies. The initial wave employed newly developed cell culture methods to produce attenuated live viruses and killed viruses for use as vaccines. The next wave began with t...
Safety and Immunogenicity of HPV16 E7/Algammulin
Ian H. Frazer, Robert W. Tindle, Germain J.P. Fernando, Karen Malcolm, Karen Herd, Sue McFadyn, Peter D. Cooper and Bruce Ward
T E6 and E7, are together sufficient to immortalize human keratinocytes in vitro,1,2 and the open reading frames encoding these viral proteins are preserved in HPV-associated cervical cancers.3,4 Humoral immune responses to the E7 protein of HPV16 have been observed in 20-50% of patients with cer...
Recombinant Vaccinia Virus
Stephen Man, E.M.L. Evans, M. Nimako and L.K. Borysiewicz
Cervical cancer is the second most common female malignancy worldwide and remains a clinical problem despite improvements in early detection and therapy. Cervical cancer (and preinvasive CIN3) is strongly associated with infection by human papillomavirus (HPV), particularly types 16 and 18.1 This...
Anti-Tumor Immunotherapy with Synthetic Peptides Representing Tumor-Associated T-Cell Epitopes: Implications for Peptide-Based Vaccination of Cervical Cancer
Maaike E. Ressing, René E.M. Toes, Stephen P. Schoenberger, Remco M.P. Brandt, Joan H. de Jong, W. Martin Kast, Rienk Offringa and Cornelis J.M. Melief
Alternative approaches for the prevention or treatment of cancer are now emerging. The goal of new treatment modalities is to combine effective anti-tumor activity with a reduction of the side effects to healthy tissues, still constituting a severe complication of conventional cancer therapy (i.e...
Vaccine for Genital Warts
John St. Clair Roberts, Terry O’Neill, Charles Lacey, David Rowen, Jane Sterling, Eric Monteiro, Louise Clark and Stephen Thompson
G papillomavirus (HPV), principally HPV types 6 and 11.1 They are one of the most common clinically recognized sexually transmitted diseases worldwide, occurring at incidence rates of 1.5-2.5% per year in men and women aged 20-24 years in populations in the developed world.2,3 For example, in the...
HPV Vaccines for Protection Against Infection
Kathrin U. Jansen
The purpose of this chapter is to describe the rationale and scientific evidence for the development of prophylactic human papillomavirus (HPV) vaccines based on the use of recombinant HPV virus-like particles. HPV-Associated Diseases Human papillomaviruses (HPVs) infect cutaneous, genital and r...
Immunobiology of HPV Infection
Graham R. Leggatt and Ian H. Frazer
T of epithelial cells. An understanding of the viral life cycle, models of infection and the host immune response is an essential first step in the development of therapeutic or prophylactic vaccines. The literature suggests that strategies to elicit neutralizing anti-capsid protein antibodies wi...
Immunomodulation of HPV Infection and Disease: An Overview
Robert W. Tindle
About 50 of the approximately 100 (the number continues to grow) genotypes of human papillomaviruses (HPV) infect the mucous epithelium of the genital tract. HPV genotypes 6, 11, 43 and 44, in particular, predispose individuals to noninvasive flat or hyperkeratotic condylomata (genital warts) and...
